Trial Profile
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Subjects With Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Jul 2023
Price :
$35
*
At a glance
- Drugs Entospletinib (Primary) ; Azacitidine; Azacitidine; Cytarabine; Daunorubicin; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 06 Jun 2023 Results of a clinical efficacy report includes one patient from group A (newly diagnosed AML, MLL-r, 14-day monotherapy lead-in with ENTO) and two patients from group C monotherapy (relapsed/refractory AML, MLL-r) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 20 Aug 2020 Results published in the Clinical Cancer Research
- 15 Mar 2019 This trial has been completed in Germany (End date-2019-02-21), according to European Clinical Trials Database.